30Oct
[Video] I Wish I Knew What I Know Now: Conversations with AGG on FDA Issues - Key Due Diligence Issues to Consider When Acquiring or Investing in Life Sciences Companies or Products
AGG is pleased to present the second episode in a podcast series titled, “I Wish I Know What I Know Now: Conversations with AGG on FDA Issues,” covering key due diligence issues to consider when acquiring or investing in life science companies or products. In this episode, AGG partner Alan G. Minsk and Brian A. Teras provides an overview of the diligence process, potential red flags, common mistakes, and other factors to consider during the due diligence process. Each month, we'll release a...
By:
Arnall Golden Gregory LLP
Related
Cannabidiol (CBD) – a non-psychoactive component of cannabis with numerous claimed health benefits ...
Read More >
Add this case to your “Be Sure to Document Your Non-Discriminatory Reasons” file. An employee doin...
Read More >
The Development: The Australian Competition and Consumer Commission ("ACCC") recently issued new gui...
Read More >
We thought you might be interested in a short summary of a workshop the FTC recently held on the imp...
Read More >
Construction “of all kind” has been listed as a Critical Sector and exempt under the recent Stay a...
Read More >
Though the pay equity between men and women is legally required and politically encouraged, wage ine...
Read More >